Olanzapine/Fluoxetine Combination for Treatment-Resistant Depression: A Controlled Study of SSRI and Nortriptyline Resistance
J Clin Psychiatry 2005;66(10):1289-1297
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: This 8-week, double-blind,
multicenter study was undertaken to replicate, in a larger sample
of patients with treatment-resistant major depressive
disorder (MDD; DSM-IV criteria), the results of a pilot
study of the olanzapine/fluoxetine combination.
Method: The study was begun in August 1999.
The primary entry criterion was a history of failure to
respond to a selective serotonin reuptake inhibitor
(SSRI). Patients (N = 500) who subsequently failed to
respond to nortriptyline during an open-label lead-in phase
were randomly assigned to 1 of 4 treatment groups:
olanzapine (6-12 mg/day) plus fluoxetine (25-50
mg/day) combination, olanzapine (6-12 mg/day), fluoxetine
(25-50 mg/day), or nortriptyline (25-175 mg/day). The
primary outcome measure was baseline-to-endpoint
mean change in score on the Montgomery-Asberg
Depression Rating Scale (MADRS).
Results: At the 8-week study endpoint, MADRS
total scores decreased by a mean 8.7 points from
baseline (28.5) with the olanzapine/fluoxetine combination,
7.0 points from baseline (28.4) with olanzapine
(p = .08), 8.5 points from baseline (28.4) with fluoxetine
(p = .84), and 7.5 points from baseline (28.8) with nortriptyline (p = .30), with no significant differences among
the therapies. The olanzapine/fluoxetine combination
was associated with significantly (p <= .05) greater
improvement (decrease) in MADRS scores than olanzapine
at weeks 2, 4, 6, and 7; than fluoxetine at weeks 2
through 5; and than nortriptyline at weeks 1 through 4. A
post hoc analysis of a subgroup of patients who had an
SSRI treatment failure during their current MDD
episode (N = 314) revealed that the olanzapine/fluoxetine
combination group had a significantly (p = .005)
greater decrease in MADRS scores than the olanzapine group
at endpoint. Safety data for the olanzapine/fluoxetine
combination were similar to those for its component
Conclusions: The olanzapine/fluoxetine
combination did not differ significantly from the other therapies
at endpoint, although it demonstrated a more rapid
response that was sustained until the end of treatment.
The results raised several methodological questions,
and recommendations are made regarding the criteria
for study entry and randomization.